In addition, it was described that KRASG12D could promote Treg transformation by blocking the interferon regulatory factor 2 (IRF2), resulting in repression of IRF2/CXCL3 pathway and binding of CXCL3 to CXCR2 on MDSCs, driving immune suppression and immune therapy resistance in colorectal cancer [1,47]. This evidence concerns the gene CXCL3 and colorectal cancer.